Australia-based CSL acquires Vifor Pharma for $12.3 B

CSL Limited, based in Australia, and Swiss firm Vifor Pharma have entered into a definitive agreement for CSL to launch an all-cash public tender offer to acquire all publicly held Vifor Pharma shares for $179.25 per Vifor Pharma share, for an aggregate equity value for Vifor Pharma of $11.7 billion. The transaction, which has been unanimously approved by both companies’ Boards of Directors, further advances CSL’s 2030 strategy to create value by adding a highgrowth, cash generative and sustainable business which complements and expands the global leadership positions of CSL’s two business units, CSL Behring and Seqirus. CSL has a long-standing and committed presence in Switzerland, where it has been an active corporate citizen since 1949 and currently has a team of more than 1,800 people on the ground in R&D, manufacturing and other operations. Since 2000, CSL Behring has invested CHF 1,257 million into its Bern facilities to meet the growing global patient demand for its immunoglobulin medicines.